Saskatchewan will have access to research material from Ontario after that province investigates new cancer treatments.

 

Saskatchewan has just joined the Joint Oncology Drug Review. Meaning effective March 1st, manufacturers of cancer treatments will only have to make one submission for review before provinces can approve that treatment for patients.

Saskatchewan Cancer Society Executive Director Keith Karison was very pleased when he learned about the partnership. "It means that provincial governments and their health departments will not have to dedicate resources to have an independent review process so this should streamline the process both financially and in terms of getting that information and making a decision on funding that drug in each province."

Cancer Care Ontario has been chosen to do the review process with other provinces having complete access to the results.